We are live on ! Find out more
ACOR

Acorda Therapeutics

Delisted

ACOR was delisted on the 11th of April, 2024.

162 hedge funds and large institutions have $1.47B invested in Acorda Therapeutics in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 63 increasing their positions, 45 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

40% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 45

7% more funds holding

Funds holding: 152162 (+10)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less capital invested

Capital invested by funds: $1.57B → $1.47B (-$95M)

38% less call options, than puts

Call options by funds: $2.85M | Put options by funds: $4.62M

Holders
162
Holders Change
+10
Holders Change %
+6.58%
% of All Funds
4.66%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
26
Increased
63
Reduced
45
Closed
15
Calls
$2.85M
Puts
$4.62M
Net Calls
-$1.77M
Net Calls Change
-$2.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$160M +$15.4M +3,766 +11%
UBS AM
2
UBS AM
Illinois
$99.7M +$9.98M +2,448 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$93.8M +$298K +73 +0.3%
BFA
4
BlackRock Fund Advisors
California
$89.4M -$4.84M -1,187 -5%
EAM
5
Eagle Asset Management
Florida
$80.6M +$9.58M +2,349 +13%
OIM
6
Oracle Investment Management
Connecticut
$65.1M -$848K -208 -1%
State Street
7
State Street
Massachusetts
$44.3M -$2.55M -625 -5%
BIT
8
BlackRock Institutional Trust
California
$41.5M +$995K +244 +2%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$41.5M +$1.77M +435 +4%
BM
10
Bridger Management
New York
$37.8M +$38.1M +9,333 New
ClearBridge Investments
11
ClearBridge Investments
New York
$33.7M +$114K +28 +0.3%
BBA
12
Baker Bros. Advisors
New York
$30.5M -$3.19M -782 -9%
Thrivent Financial for Lutherans
13
Thrivent Financial for Lutherans
Minnesota
$30M +$8.15K +2 +0%
Invesco
14
Invesco
Georgia
$28.7M -$13.7M -3,350 -32%
Citadel Advisors
15
Citadel Advisors
Florida
$26.2M +$19.2M +4,713 +266%
Norges Bank
16
Norges Bank
Norway
$25.2M +$13.9M +3,411 +121%
Millennium Management
17
Millennium Management
New York
$23.8M +$24M +5,880 New
SI
18
Scout Investments
Missouri
$23M +$387K +95 +2%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$22.6M -$57.1K -14 -0.2%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$20.8M +$20.9M +5,130 New
PCM
21
Penn Capital Management
Pennsylvania
$19.9M +$8.47M +2,078 +73%
VOYA Investment Management
22
VOYA Investment Management
Georgia
$19.3M -$1.63M -400 -8%
BA
23
BlackRock Advisors
Delaware
$18.6M -$5.11M -1,252 -21%
Northern Trust
24
Northern Trust
Illinois
$17.3M -$2M -490 -10%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$16.3M -$832K -204 -5%

ACOR Hedge Fund Activity: Q2 2014 in Review

162 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2014, worth a combined $1.47B — down 6.1% from $1.57B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 15 closed out — a net gain of 11 holders — while 63 added to existing stakes and 45 trimmed.

The largest buyer was Bridger Management, opening a new position worth an estimated $38.1M. The largest seller was Franklin Resources, exiting entirely with an estimated $35.7M sold.

  • 162 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2014, up from 152 in Q1 2014.
  • Funds reported $1.47B of Acorda Therapeutics stock for Q2 2014, down 6.1% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q2 2014 and 15 closed out, a net change of +11 holders.
  • The largest Acorda Therapeutics buyer in Q2 2014 was Bridger Management, an estimated $38.1M added.
  • The largest Acorda Therapeutics seller in Q2 2014 was Franklin Resources, an estimated $35.7M sold.

Based on aggregated 13F filings for Q2 2014.